The decisions that determine Phase 2 timing are made, or missed, in the first two quarters after the IND opens.
White Paper
IND Ready Is Not Phase 2 Ready
Related Resources
All Resources
case-study
From Data to Dossier: Smart Scale-Up Solutions in Biopharmaceutical Manufacturing
Read More
infographic
Cracking the Code: Syner-G’s Blueprint for Success with Pharmaceutical Stability Studies
Read More
white-paper
Stability Study Design: Pharmaceutical Stability and Data Evaluation
Read More
post
Biologics vs Small Molecules: A New Era in Drug Development
Read More
Let's move from science to success.
Let’s Talk